of the Cleveland Clinic in Cleveland, Ohio, presented the long-awaited results of the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial at the plenary session of the American Federation for Clinical Research in Washington, DC, on April 30, 1993. This "megatrial" randomized a total of 41 021 patients with acute myocardial infarction (up to 6 hours of chest pain plus ECG evidence of infarction) to four treatment regimens: (1) front-loaded tissue-type plasminogen activator (t-PA) with intravenous heparin; (2) front-loaded t-PA plus streptokinase with intravenous heparin; (3) streptokinase plus intravenous heparin; and (4) streptokinase plus subcutaneous heparin. The primary end point of the study was 30-day mortality. Secondary end points included 24-hour and 1-year mortality and 30-day net clinical benefit (number of patients alive and free from disabling stroke). An angiographic substudy of 2400 patients examined patency rates at one of four time points (90 minutes, 180 minutes, 24 hours, and 7 days) after thrombolytic administration.
Meeting Highlights
James J. Ferguson III, MD GUSTO Trial Dr Eric Topol of the Cleveland Clinic in Cleveland, Ohio, presented the long-awaited results of the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial at the plenary session of the American Federation for Clinical Research in Washington, DC, on April 30, 1993. This "megatrial" randomized a total of 41 021 patients with acute myocardial infarction (up to 6 hours of chest pain plus ECG evidence of infarction) to four treatment regimens: (1) front-loaded tissue-type plasminogen activator (t-PA) with intravenous heparin; (2) front-loaded t-PA plus streptokinase with intravenous heparin; (3) streptokinase plus intravenous heparin; and (4) streptokinase plus subcutaneous heparin. The primary end point of the study was 30-day mortality. Secondary end points included 24-hour and 1-year mortality and 30-day net clinical benefit (number of patients alive and free from disabling stroke). An angiographic substudy of 2400 patients examined patency rates at one of four time points (90 minutes, 180 minutes, 24 hours, and 7 days) after thrombolytic administration.
With regard to the primary end point of the study, the use of a front-loaded t-PA group resulted in significantly lower 30-day mortality (6.3% vs 7.3% in the two streptokinase groups and 7.0% in the combination t-PA/ streptokinase regimen). There was a higher incidence of total stroke in the front-loaded t-PA group (1.55% vs 1.22% in the two streptokinase groups); however, the net clinical benefit favored front-loaded t-PA (6.9% in the t-PA group, 7.9% in the streptokinase plus intravenous heparin group, and 7.7% in the streptokinase plus subcutaneous heparin group). In the angiographic substudy, 90-minute patency (TIMI flow grade 2 or 3) was significantly higher in the front-loaded t-PA group (80.8% vs 73.1% in the streptokinase/t-PA group, 61% in the streptokinase/intravenous heparin group, and 55.6% in the streptokinase/subcutaneous heparin group). At 180 minutes, 24 hours, and 5 to 7 days, there were no significant differences in patency rates between groups. The incidence of reocclusion was low in all four groups.
Overall 30-day mortality was 4.3% for patients who achieved TIMI grade 3 flow, compared with 7.9% for patients with TIMI grade 2 flow and 9.0% for patients with TIMI grade 1 flow. One very impressive factor related to mortality was the speed with which thrombolytic therapy was administered. Thirty-day mortality was 5.4% in patients who received front-loaded t-PA in <2 hours after chest pain, compared with 6.6% in patients who received t-PA between 2 and 4 hours after chest pain and 9.4% in patients treated between 4 and 6 hours. Elderly patients had a 30-day mortality of 20.6%.
On behalf of the GUSTO Investigators, Dr Topol concluded that for every 1000 patients treated, frontloaded t-PA will save 10 more lives than streptokinase. This difference in mortality appears to be related to earlier infarct vessel patency in the t-PA group. Intravenous heparin conveys no identifiable benefit in the streptokinase group, and the combination of streptokinase and t-PA was not as good as t-PA alone and no better than streptokinase alone. TIMI grade 3 flow and early administration of thrombolytic therapy appear to convey additional survival benefits.
The finding that even with the best strategy only 55% of patients had TIMI grade 3 flow suggests that even further improvement in the treatment of acute myocardial infarction may be possible in the future. It appears that the early open vessel hypothesis is finally validated.
Gene Therapy in Human Bronchial
Epithelial Cells Also at the American Federation of Clinical Research meeting, Dr Patricia Lemarchand from the National Heart, Lung, and Blood Institute in Bethesda, Md, presented data on in vitro gene therapy in human bronchial epithelial cells. The authors designed a replication-deficient recombinant adenovirus (AdCL) containing human catalase complementary DNA (cDNA) to transfer the catalase cDNA to human bronchial epithelial cells (obtained by cytological brush) to augment intracellular protection against oxidant-mediated (H202) epithelial injury. AdCL-infected cells expressed AdCL-driven catalase mRNA and had a threefold to eightfold increase in catalase activity compared with controls 1 to 7 days after infection.
In addition, cells from a human bronchial epithelial cell line from a cystic fibrosis patient were infected with AdCL and 3 days later were exposed to lethal doses of H202 for 1 day. The majority of AdCL-infected cells survived, in contrast to cells infected with a control virus, which were dead or significantly damaged.
In a separate series of experiments, AdCL was also administered in vivo into rat airways, and AdCL-driven catalase mRNA was detected by Northern analysis.
Dr Lemarchand concluded that a recombinant adenovirus containing human catalase cDNA is able to infect bronchial epithelial cells in vitro and protect against oxidant-mediated injury. Her group has also demonstrated the ability to successfully transfer catalase cDNA to the lungs in vivo in an animal model. Heparin Therapy After Myocardial Infarction:
Results of the TIMI 4 Study Dr Greg C. Flaker of the University of Missouri in Columbia, Mo, presented data from the Thrombolysis in Myocardial Infarction (TIMI) group on the use of standardized heparin nomograms to direct anticoagulation therapy after myocardial infarction. In TIMI-4, patients with myocardial infarction were randomized to either tissue-type plasminogen activator (t-PA), anisoylated plasminogen streptokinase activator complex (APSAC), or both, with all patients receiving intravenous heparin therapy within 6 hours of the onset of chest pain. Intravenous heparin was continued for 4 days unless contraindicated, with daily partial thromboplastin time (PTT) monitoring. Nine participating centers (group 1) used the following standardized heparin nomogram: activated PTT (aPTT) >3xcontrol, decrease heparin by 50%; aPTT 2 to 3 x control, decrease heparin by 25 %; aPTT < 1.5 x control, increase heparin by 25%. Six centers (group 2) did not rely on a nomogram for heparin dosing. There were fewer group 1 patients with aPTT < 1.5 x control at most time points (1% vs 7% in group 2 at 8 hours, 15% vs 5% at 18 hours, 26% vs 32% at 24 hours, 37% vs 55% at 48 hours, 41% vs 32% at 72 hours, and 21% vs 53% at 96 hours). Patients with subtherapeutic aPTT at 24 hours tended to be younger (55+± 11 vs 60±11 years) and heavier (86±13 vs 79±16 kg). Dr Flaker concluded that a substantial number of patients receive subtherapeutic anticoagulation after myocardial infarction. The use of a standardized nomogram improved anticoagulation somewhat, but refinements in heparin dosing based on age and weight may lead to further improvements in the efficacy of therapy.
Cardiac Autoantibodies in Chagas' Disease Dr David M. Engman of Northwestern University in Chicago, Ill, presented an animal study examining the potential role of cardiac autoimmunity in a mouse model of Trypanosoma cruzi infection (Chagas' disease). Specifically, the authors sought to determine whether cardiac antigen-specific antibodies are produced in T. cruzi-infected mice with heart disease and, if so, to determine their antigen specificities. In one series of experiments, C57BL/6 mice were infected with the Brazil strain of T. cruzi. Antisera from these mice reacted with four cardiac antigens with relative molecular masses of 37, 53, 150, and 200 kD. The larger two antigens, p150 and p200, are specific for heart muscle, whereas p53 and p37 are found in skeletal muscle as well. In a second series of experiments, C57BL/6 mice infected with the Guayas strain of T. cruzi (who do not develop cardiomyopathy) did not produce antibodies to p200, p150, or p53, suggesting that these autoantibodies may be specific markers for cardiomyopathy. In addition, p53 and p200 have been identified as the intermediate filament protein, desmin, and the cardiac contractile protein, myosin, respectively. The findings in this study are corroborated by the fact that autoantibodies to both desmin and cardiac myosin have been detected in humans with cardiomyopathy and other experimental animal models of cardiomyopathy. Dr Engman concluded that infection with particular strains of T. cruzi autoimmune disease, possibly involving one or more of the antigens identified in this study.
Superoxide Anion Production After Balloon Injury
Dr Steven V. Manoukian of Emory University in Atlanta, Ga, presented an animal study examining superoxide anion production (02-) after balloon injury in a porcine model. 02rapidly inactivates nitric oxide, has vasoconstrictor effects, and may be one factor contributing to the relation of balloon injury to subsequent abnormalities in vascular tone. To test the hypothesis that 2-production is increased after balloon injury, segments were excised from normal and ballooninjured porcine coronary arteries 28 days after injury. A lucigenin chemiluminescence assay was used to determine 02 production in samples with and without endothelium. In comparison with normal segments, injured arterial segments had a more than twofold increase in 2-production. The presence or absence of endothelium did not appear to affect 02production in either normal or injured segments. Dr Manoukian concluded that 2-production is dramatically increased 4 weeks after balloon injury in porcine coronary arteries; the production of 02 in this setting does not appear to be endothelial in origin.
Stroke Prevention in Atrial Fibrillation Dr Jonathan Halperin of Mount Sinai Medical Center in New York presented the preliminary results of the second Stroke Prevention in Atrial Fibrillation (SPAF II) trial at the recent American College of Cardiology meetings in Anaheim, Calif. The purpose of this study was to determine the relative efficacies of Coumadin vs aspirin in preventing strokes in patients with atrial fibrillation. Additional analyses were also directed at the risk/benefit ratios of aspirin and Coumadin in elderly and nonelderly patients. A total of 1090 patients with nonvalvular atrial fibrillation were grouped according to age (715 patients <75 years, 375 patients 275 years), and both of the two age groups were randomized to receive Coumadin (adjusted to an International Normalized Ratio of 2 to 2.5) or enteric coated aspirin (325 mg/day). In the patients <75 years old, the Coumadin group had a 26% reduction in the incidence of ischemic strokes (1.4% vs 1.9% per year in the aspirin group); however, Coumadin was also associated with an increase in the rate of intracranial hemorrhage (0.6% vs 0.2% per year in the aspirin group) and all major hemorrhages (1.8% vs 0.8% per year in the aspirin group).
In patients >75 years old, the overall risks of stroke and hemorrhage were significantly higher. The Coumadin group had a 30% reduction in ischemic stroke (3.4% vs 4.9% per year in the aspirin group). Coumadin was associated with a much higher risk of bleeding in the elderly group: the incidence of intracranial hemorrhage was 1.8% per year in the Coumadin group vs 0.8% per year in the aspirin group; the incidence of all major hemorrhages was 5.0% per year in the Coumadin group vs 1.6% per year in the aspirin group.
Additional analyses were performed to determine the predictors of thromboembolic events in patients already on aspirin. These predictors included age >75 years (especially in women), systolic hypertension (systolic blood pressure, >160), and impaired left ventricular may lead to the development of cardiac antigen-specific function (ejection fraction, <25%) or recent congestive heart failure.
Dr Halperin concluded that the bleeding risks of Coumadin do not generally outweigh the potential advantage over aspirin in preventing strokes. Patients at low risk for stroke or who have a low risk of complications of therapy would benefit from aspirin. Patients who have a high risk of stroke despite aspirin therapy may benefit from Coumadin, but the risks of bleeding must be considered, especially in the elderly population.
A Meta-Analysis of Coronary Bypass Surgery Trials Also at the American College of Cardiology meeting in Anaheim, Calif, Dr Salim Yusuf of McMaster University in Hamilton, Ontario, presented data from a meta-analysis of the six major randomized studies comparing coronary artery bypass graft surgery (CABG) and medical therapy: the European Study, the VA trial, CASS, the Oregon study, the Texas study, and two studies from Auckland, New Zealand. Dr Yusuf presented the pooled 7-year follow-up data from an ongoing collaborative project that used original data from the six studies. He emphasized that these studies all reflect the surgical technique and associated complications from the early 1970s and that the population that entered these studies was a function of patients undergoing surgery at the time, which differs from today's surgical population. In the total of 2499 patients in the meta-analysis, the mean age was 51 years, with 97% men; 11% had no angina, 54% had mild angina, and 35% had moderate to severe angina. The mean ejection fraction was 59%; 21% of patients had an abnormal ejection fraction (<50%). Ten percent had single-vessel disease, 32% had two-vessel disease, 51% had three-vessel disease, and 7% had left main disease. Only 10% of grafts used the internal mammary artery.
Overall, surgical therapy had a 33% reduction in 7-year mortality compared with medical therapy. There was a highly significant reduction in mortality in the left main group, with a nearly 70% reduction in mortality. In three-vessel disease, there was a 45% reduction in mortality in the surgical group. In one-and two-vessel disease groups, there were far fewer events, and the trend favoring surgery was much weaker, although certain high-risk subsets appeared to benefit. Interestingly, both patients with low ejection fractions and those with normal ejection fractions showed benefit with surgery, with reductions in mortality of about 50% and 30%, respectively. Furthermore, patients with a positive exercise test had greater benefit than those without a positive exercise test, but both groups showed benefit, as did the groups of patients with and without angina. This strongly suggests that extent of coronary artery disease and ventricular function are major risk factors for mortality, much more so than symptom severity.
Dr Yusuf summarized by stating that the overall 7-year data demonstrate a clear survival benefit for surgery over medical therapy. The greater the extent of disease, the greater the benefit. The absolute benefit also appears greatest in patients at highest risk, for example, those with low ejection fractions, severe angina, and elderly patients. Thus, there appears to be a role for CABG surgery even in the absence of disabling symptoms; this role relates to patient characteristics that indicate higher risk of death and the potential for greater relative benefit.
